Predictive Oncology (Predictive Oncology) Forward Dividend Yield % : 0.00% (As of Apr. 30, 2024)

View and export this data going back to 2010. Start your Free Trial

What is Predictive Oncology Forward Dividend Yield %?

As of today (2024-04-30), the Forward Annual Dividend Yield of Predictive Oncology is 0.00%.

As of today (2024-04-30), the Trailing Annual Dividend Yield of Predictive Oncology is 0.00%.

POAI's Forward Dividend Yield % is not ranked ^*
in the Medical Devices & Instruments industry.
Industry Median: 1.93
* Ranked among companies with meaningful Forward Dividend Yield % only.

Predictive Oncology's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Predictive Oncology's Forward Dividend Yield %

For the Medical Instruments & Supplies subindustry, Predictive Oncology's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Predictive Oncology's Forward Dividend Yield % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Predictive Oncology's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Predictive Oncology's Forward Dividend Yield % falls into.

Predictive Oncology Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Predictive Oncology (NAS:POAI) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Predictive Oncology Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Predictive Oncology's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Oncology (Predictive Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Predictive Oncology Inc (NAS:POAI) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2915 Commers Drive, Suite 900, Eagan, MN, USA, 55121

Website

https://www.predictive-oncology.com

Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Helomics, zPREDICTA, Soluble and Skyline. It derives prime revenue from the Skyline segment which consists of the STREAMWAY System product sales, and TumorGenesis subsidiary (Research and Development) is included within corporate. The STREAMWAY System virtually eliminates staff exposure to blood, irrigation fluid, and other potentially infectious fluids found in the healthcare environment. Its Helomics division is focused on improving the effectiveness of cancer therapy using proprietary, multi-omic tumor profiling platform, a one-of-a-kind database of historical tumor data, and the power of AI to build predictive models of tumor drug response.

Executives

Robert L Myers	officer: CHIEF FINANCIAL OFFICER	4765 BEACON HILL ROAD, EAGAN MN 55122
Nuzum Charles Lee Sr	director	633 1ST STREET WEST, SONOMA CA 95476
Veena Rao	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Matthew Hawryluk	director	C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
St. Clair Gregory Sr	director	1645 WHITLEY DRIVE, HARRISBURG PA 17111
Nancy Chung-welch	director	P O BOX 1572, PEPPERELL MA 01463
Pamela Bush	officer: Chief Business Officer	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Daniel E Handley	director	1142 S. DIAMOND BAR BLVD. #464, DIAMOND BAR CA 91765
Raymond F Vennare	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
David Stewart Smith	director	151 WASHINGTON STREET, PITTSBURGH PA 15218
J Melville Engle	director	1 REMINGTON COURT, NAPA CA 94558
Jenkins Christina Lee Md	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121
Carl I. Schwartz	10 percent owner	20155 N.E. 38TH COURT, UNIT 3104, AVENTURA FL 33180
Richard L Gabriel	director	900 COCOANUT AVENUE, SARASOTA FL 34236
Pamela S Prior	director	2915 COMMERS DRIVE, SUITE 900, EAGAN MN 55121